In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

Brian Abrahams of RBC Capital initiated an “Outperform” rating for Vertex Pharmaceuticals Incorporated (VRTX), paving the way for potential upside for investors. With a current price of $461.14 and a ...

Parnassus Growth Equity Fund (Investor Shares) returned 3.93% (net of fees) during the quarter, outperforming the Russell ...

Major indices closed higher on Wednesday after Donald Trump called off new tariffs on European nations, claiming that a deal ...

Zoetis Inc. (NYSE: ZTS) was assigned a “Neutral” rating by analyst David Westenberg from Piper Sandler. This rating comes with a price target of $135, suggesting an upside potential from the current ...